Effects of 0.5% and 2.0% Sodium Lauryl Sulfate in Male CD-1 Mice From a 3-Month Oral Gavage Toxicity Study

Author:

Irizarry Rovira Armando R.1ORCID,Hilbish Kim G.2,Schroeder Matthew3,Boorman Gary A.4,Credille Kelly M.5,Ballard Darryl5,Hanson Jeff C.6,Niedenthal Andrea7

Affiliation:

1. Department of Pathology, Eli Lilly and Company, Indianapolis, IN, USA

2. Nonclinical Safety Assessment, Covance Laboratories Inc, Greenfield, IN, USA

3. Nonclinical Safety Assessment, Covance Laboratories Inc, Madison, WI, USA

4. Nonclinical Safety Assessment, Covance Laboratories Inc, Chantilly, VA, USA

5. Diagnostic and Experimental Pathology Laboratory, Eli Lilly and Company, Indianapolis, IN, USA

6. Research Informatics, Eli Lilly and Company, Indianapolis, IN, USA

7. Nonclinical Study Management, Eli Lilly and Company, Indianapolis, IN, USA

Abstract

The tolerability of single daily gavage doses of 0.5% or 2.0% (wt/vol) sodium lauryl sulfate (SLS) in 11- to 12-week-old male CD-1 mice was evaluated in a study of 3 months in duration. Live-phase, gross necropsy, and histopathologic parameters were evaluated. Mortality of 14% occurred in mice administered formulations containing SLS. Clinical observations in mice administered SLS included abnormal respiration (audible, irregular, and/or labored), swollen abdomen, rough haircoat, hunched appearance, and hypoactivity. Necropsy findings in mice administered SLS consisted of enlarged intestines containing abnormal contents with gas. There were no instances of mechanical gavage–related injury. Histologic evaluation of the respiratory tract revealed injury to the nasal passages and nasopharynx, including, but not limited to, inflammation, exudate, apoptosis/necrosis of epithelium, and atrophy of epithelium or olfactory nerves. Collectively, the data indicated that under the experimental conditions of our 3-month study in male CD-1 mice, once-daily gavage administration of vehicle formulations containing SLS at 0.5% or 2.0% resulted in nasal injury and 14% mortality supportive of gastroesophageal reflux. Sponsors utilizing formulations containing SLS in toxicity studies in CD-1 mice should exclude gastroesophageal reflux as a confounding factor in studies with morbidity or mortality associated with respiratory distress or evidence of aerophagia.

Funder

Eli Lilly and Company

Publisher

SAGE Publications

Subject

Cell Biology,Toxicology,Molecular Biology,Pathology and Forensic Medicine

Reference36 articles.

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. M3(R2). Published June 11, 2009. Accessed May 18, 2018. https://database.ich.org/sites/default/files/M3_R2__Guideline.pdf

2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Preclinical safety evaluation of biotechnology-derived pharmaceuticals. S6(R1). Published June 2011. Accessed May 18, 2018. https://database.ich.org/sites/default/files/S6_R1_Guideline_0.pdf

3. A Brief Overview of the STP 35th Annual Symposium on the Basis and Relevance of Variation in Toxicologic Responses

4. Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3